Trial Profile
A Randomised, Double-Blind (Sponsor-Unblind), Placebo Controlled, Cross-Over Study to Investigate the Efficacy, Effect on Cough Reflex Sensitivity, Safety, Tolerability and Pharmacokinetics of Inhaled GSK2339345 in Patients With Chronic Idiopathic Cough Using an Aqueous Droplet Inhaler
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 2339345 (Primary)
- Indications Cough
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 06 Jul 2017 Primary endpoint has not been met. (Total Cough Count Over 8 Hours at Visits 1, 2 and 3 (Part A)) as per results published in the International Journal of Clinical Pharmacology and Therapeutics
- 06 Jul 2017 Results published in the International Journal of Clinical Pharmacology and Therapeutics
- 19 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.